CASI CASI Pharmaceuticals Inc.: רווח נקי למניה אחת בשנים עשר החודשים האחרונים

The operating cash flow of CASI Pharmaceuticals (CASI) is supported by the sale of approved oncology drugs in China, as confirmed by the EPS YoY TTM dynamics, where the metric level stands at -42.10. Financial stability is based on the commercialization of licenses and the expansion of the product pipeline. Business development relies on a cross-cultural synthesis of US and Asian science, attracting specialists through large-scale investments in innovative research.

This indicator measures the annual growth rate of net income per share over a rolling 12-month period, identifying deviations in operational efficiency from historical trends. By analyzing the 12-month EPS YoY history, an investor can assess how the commercialization of oncology drugs in the Chinese market converts into real shareholder returns for CASI Pharmaceuticals (CASI), separating systemic growth from one-time accounting adjustments.